NasdaqCM - Delayed Quote • USD
Acasti Pharma Inc. (ACST)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 5:16 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.34 | -0.26 | -1.41 | -1.1 |
| Low Estimate | -0.34 | -0.26 | -1.41 | -1.1 |
| High Estimate | -0.34 | -0.26 | -1.41 | -1.1 |
| Year Ago EPS | -- | -0.39 | -4.12 | -1.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 12/31/2023 | |
|---|---|---|---|---|
| EPS Est. | -- | -0.66 | -0.61 | -0.22 |
| EPS Actual | -- | -0.39 | -2.82 | -0.22 |
| Difference | -- | 0.27 | -2.21 | 0 |
| Surprise % | -- | 40.90% | -362.30% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.34 | -0.26 | -1.41 | -1.1 |
| 7 Days Ago | -0.35 | -0.27 | -1.44 | -1.12 |
| 30 Days Ago | -0.35 | -0.27 | -1.43 | -1.11 |
| 60 Days Ago | -0.35 | -0.27 | -1.43 | -1.11 |
| 90 Days Ago | -0.09 | 0 | -0.34 | -0.41 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACST | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | 33.30% | -- | -- | 9.60% |
| Current Year | 65.80% | -- | -- | 4.50% |
| Next Year | 22.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Related Tickers
CYCN Cyclerion Therapeutics, Inc.
3.4541
+6.28%
HOTH Hoth Therapeutics, Inc.
1.1800
-4.07%
ENTX Entera Bio Ltd.
2.2400
+0.90%
OGEN Oragenics, Inc.
1.1300
+4.63%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1570
-1.51%
IBIO iBio, Inc.
1.7700
-6.35%
NRBO NeuroBo Pharmaceuticals, Inc.
3.4400
-0.58%
LVTX LAVA Therapeutics N.V.
2.8300
-3.74%
PMVP PMV Pharmaceuticals, Inc.
1.6200
+0.62%
PIRS Pieris Pharmaceuticals, Inc.
0.1552
-1.21%